53. Sjogren syndrome Clinical trials / Disease details


Clinical trials : 283 Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04830644
(ClinicalTrials.gov)
March 22, 202128/3/2021A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Iguratimod in Patients With Active Primary Sjogren's Syndrome.Primary Sjögren SyndromeDrug: Iguratimod;Drug: PlaceboJiangsu Simcere Pharmaceutical Co., Ltd.NULLRecruiting18 Years75 YearsAll144Phase 2China
2ChiCTR1900024642
2019-08-012019-07-19Clinical Study of Iguratimod in the Treatment of Primary Sjogren's SyndromeClinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome Primary Sjogren's SyndromeExperimental group:Iguratimod+Prednisone;control group:HCQ+Prednisone;Chongqing Hospital of Traditional Chinese MedcineNULLRecruiting1865BothExperimental group:30;control group:30;N/AChina
3ChiCTR1900021345
2019-02-122019-02-16Effect of Iguratimod on Primary Sjogren's SyndromeObservation of Iguratimod's Effect on Primary Sjogren's Syndrome, A randomized, double-blind, placebo-controlled trial Primary Sjogren's SyndromeControl group :Hydrochloroquine;Treatment group:Iguratimod;Tianjin Medical University General HospitalNULLRecruiting1875BothControl group :30;Treatment group:30;China
4NCT03023592
(ClinicalTrials.gov)
February 201715/1/2017Study of Iguratimod in Sjögren's SyndromeA Preliminary Efficacy Study of Iguratimod in Patients With Sjögren's SyndromeSjogren's SyndromeDrug: IguratimodPeking Union Medical College HospitalNULLRecruiting18 Years75 YearsAll30Phase 1/Phase 2China